Science Driven. Nature Inspired. Future Focused.
A deep-tech biopharmaceutical company grounded in Asian medicinal heritage — not a traditional TCM practitioner, but a science-driven innovator advancing nature-derived therapeutics.
Press & media
Partnership
Nanyang Biologics Announces $1.5 Billion Business Combination with RF Acquisition Corp II to Pursue Nasdaq Listing
Nanyang Biologics announced the signing of a business combination agreement with RF Acquisition Corp II, aiming to bring NYB to the public markets.
Partnership
Powering Life Sciences and Health Innovation - A Global AI Alliance from Singapore
Nanyang Biologics hosts AI4Life Summit 2025 with global partners – NVIDIA, Hewlett Packard Enterprise, and Equinix – to accelerate AI-Driven biomedical innovation
Company
Nanyang Biologics is the Winner of SuperAI Genesis 2025
Nanyang Biologics has been crowned the 1st Prize Winner of the SuperAI Genesis Startup Competition 2025, the world’s premier AI startup showdown at SuperAI Singapore 2025.
Featured news
Partnership
Nanyang Biologics Announces $1.5 Billion Business Combination with RF Acquisition Corp II to Pursue Nasdaq Listing
Nanyang Biologics announced the signing of a business combination agreement with RF Acquisition Corp II, aiming to bring NYB to the public markets.
Partnership
Powering Life Sciences and Health Innovation - A Global AI Alliance from Singapore
Nanyang Biologics hosts AI4Life Summit 2025 with global partners – NVIDIA, Hewlett Packard Enterprise, and Equinix – to accelerate AI-Driven biomedical innovation
Company
Nanyang Biologics Featured in Equinix Global Case Study on AI-Powered Drug Discovery
Nanyang Biologics has been featured as a global case study by @Equinix, showcasing how our AI-driven drug discovery is powered by scalable and secure infrastructure.
